Behçet's disease is an multifactorial multi-system auto-inflammatory vasculitis characterized by recurrent oral -and genital ulcers, uveitis, and skin lesions. The first series of patients with Behçet's disease was already published in 1937 as a triad of these symptoms. As in other immune mediated disorders Behçet's disease is characterised by attacks rather than by a persistent inflammatory disease. Cases of Behçet's disease cluster along the ancient Silk Road, extending from eastern Asia to the Mediterranean basin. The prevalences vary between 70 and 420 per 100.000 in Turkey to <1 per 100.000 in Northern European. It is believed that both genetic and environmental factors contribute to the development of the disease. Susceptibility to Behçet's disease is strongly associated with the presence of the HLA-B51 allele and its presence is also strongly associated with a more aggressive course. Although the exact cause of Behçet's disease remains to be elucidated, it is clear that neutrophils interacting with T-cells play an important role in the pathophysiology. The activated T-cells produce TNF-α, which in turn leads to production of other pro-inflammatory cytokines yielding significant inflammation at sites usually located at the first line of immunological defence involving the innate immunity.

Most immunosuppressive agents can be used to treat patients with Behçet's disease, however the level of evidence is limited since there are few randomized controlled trials. Treatment of patients with Behçet's disease is directed by the presence of organ involvement, or vision –or life-threatening situations and is usually given in a step up approach. TNF blockers represent a novel regimen in the treatment of Behçet's disease and is regarded standard third line treatment.

The international conferences on Behçet’s Disease is the main event for physicians and researchers interested in Behçet’s disease. The contributors provide  top oral presentations and poster sessions of accepted abstracts on a wide range of topics including basic immunology, genetics and clinical innovations. Meet-the-expert sessions will give young physicians an opportunity to share experiences with experts in the field. Extra breakfast and lunch sessions will allow those interested in development of new therapies to gain knowledge and contacts. To challenge our honorable members we will invite distinguished speakers on the topics innate  immunity, genetics, clinics, including innovative therapies.